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Abstract 
Genetic data is now collected in many clinical trials, especially in population pharmacokinetic 
studies. There is no consensus on methods to test the association between 
pharmacokinetics and genetic covariates. We performed a simulation study inspired by real 
clinical trials, using the PK of a compound under development having a nonlinear 
bioavailability along with genotypes for 176 Single Nucleotide Polymorphisms (SNPs). 
Scenarios included 78 subjects extensively sampled (16 observations per subject) to simulate 
a phase I study, or 384 subjects with the same rich design. Under the alternative hypothesis 
(H1), 6 SNPs were drawn randomly to affect the log-clearance under an additive linear 
model. For each scenario 200 PK data sets were simulated under the null hypothesis (no 
gene effect) and H1. We compared 16 combinations of four association tests, a stepwise 
procedure and three penalised regressions (ridge regression, Lasso, HyperLasso), applied to 
four pharmacokinetic phenotypes, two observed concentrations, area under the curve 
estimated by noncompartmental analysis and model-based clearance. The different 
combinations were compared in terms of true and false positives and probability to detect 
the genetic effects. In presence of nonlinearity and/or variability in bioavailability, model-
based phenotype allowed a higher probability to detect the SNPs than other phenotypes. In 
a realistic setting with a limited number of subjects, all methods showed a low ability to 
detect genetic effects. Ridge regression had the best probability to detect SNPs, but also a 
higher number of false positives. No association test showed a much higher power than the 
others. 
Keywords: noncompartmental analysis, nonlinear mixed effects models, penalised 
regression, pharmacogenetics, pharmacokinetics  
 
Abbreviations: FWER, Family wise error rate; LOQ, Limit of quantification; NCA, 
Noncompartmental analysis; NLMEM, Nonlinear mixed effects model; PK, Pharmacokinetics; 
SNP, Single nucleotide polymorphism; α, Type I error; β, Effect size coefficient; λ, γ, ξ, 
Penalisation parameters. 
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INTRODUCTION 
Personalized care development should improve efficacy of drugs, and limit the risks 
associated with their use (1) , and is particularly beneficial for drugs with narrow therapeutic 
margin and variability in response. Pharmacogenetics (2,3) studies the proportion of 
interindividual variability in drug response that can be explained by genetic variation, 
investigating specifically the link between the genotype and the pharmacokinetic (PK)/ 
pharmacodynamic (PD) (4) phenotype. In PK/PD studies, phenotypes can be observed (e.g. 
residual concentrations, biomarker measurements) or estimated (e.g. total exposure or 
specific PK parameters). 
Estimated phenotypes in PK are mainly derived through two methods. The 
noncompartmental analysis (NCA) (5) calculates for each subject measurements of PK 
exposure such as the area under the curve (AUC) or maximal and trough observed 
concentrations through model-free approaches. It requires rich and balanced data per 
individual, which makes it inappropriate for studies in advanced phases of drug development 
or in special populations (pediatrics…). Model-based approaches on the other hand describe 
the dynamic phenomena through a mathematical model and estimate primary PK 
parameters summarising physiological processes. These methods involve NonLinear Mixed 
Effects Models (NLMEM) (6), which jointly analyse data obtained on a set of individuals to 
determine the typical model parameters (fixed effects), and the parameters of inter and 
intraindividual variability (random effects), as well as the residual error. NLMEM are better 
suited to sparse and unbalanced data, and clinical studies can be combined to increase the 
power to detect genetic effect (7). 
Unlike monogenic diseases, caused by mutation of a single gene, the variability in PK/ PD is 
usually the product of a set of markers with low to intermediate effect sizes. The screening 
of a large number of genetic markers, such as Single Nucleotide Polymorphisms (SNP), is 
possible thanks to the development of genotyping methods and microarrays (8). This has 
two major consequences: the number of genetic variants studied tends to be larger than the 
number of subjects and some of these variants are correlated due to linkage disequilibrium 
(9). 
An exhaustive literature review about clinical pharmacogenetic studies was performed to 
gain an overview of the methods currently used in this type of study (see the supplementary 
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materials for the literature review methods we used). Information about the phenotypes 
(obtained by NCA or modelling), the design of studies, the genetic data and the statistical 
analysis have been extracted from each publication, and summarised through descriptive 
statistics. During the period 2010-2012, on 85 pharmacogenetic studies using PK parameters 
as phenotypes, 69% used NCA and 31% used modelling-based phenotypes for association 
analysis. About two thirds of the studies included less than 50 subjects and only 15% more 
than 100 subjects. A limited number of genetic covariates were studied (3 genes (minimum = 
1; maximum = 45) and 8 SNPs (minimum = 1; maximum = 198) in average). Genes were finely 
targeted because known to be involved in the PK of studied molecules. Finally, association 
between NCA-based phenotype and polymorphism were mainly investigated using 
univariate methods (univariate anova, t-test…) (57%), multivariate methods (multivariate 
linear regression) (14%) and stepwise or descriptive methods. Model-based phenotypes 
were explored using mostly stepwise regression (78%), univariate methods applied on 
individual parameter estimates (7%) or descriptive methods. 
So although health authorities strongly recommend studying the pharmacogenetics of new 
chemical entities in development (10,11), there is no consensus on analysis methods to 
explore a large number of polymorphisms in association with PK phenotypes. Specific 
approaches and statistical tools are required, which must take into account the small 
amount of PK information provided by each individual in relation to the number of genetic 
covariates, and be able to detect a signal in a large number of possible relationships. 
Penalised regression methods analyse all markers simultaneously and use a penalisation 
function which shrinks most effect coefficients to select a parsimonious set of markers of the 
phenotype variability. These methods have been especially used in Genome Wide 
Association Studies (GWAS) to binary outcomes (12) or quantitative traits (13). Here we 
evaluate three such methods: ridge regression (14) adapted to include a test of significance 
for its derived estimates (15), the Lasso (16) and the HyperLasso (17), a generalisation of the 
Lasso. 
In the present study, we propose to compare those three penalised regression methods with 
a stepwise approach through a simulation study, to assess their ability to detect the 
influence of genetic variables on the PK. We apply them to four possible PK phenotypes (two 
observed concentrations, AUC estimated by NCA, model parameters estimated by NLMEM). 
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This work is based on collaboration with the pharmaceutical industry (IRIS, Institut de 
Recherches Internationales Servier) and thus focuses specifically on issues of clinical trials for 
drug development. This also provided a real case study to design the simulations which had 
interesting features, including a nonlinear absorption, resulting from the drug's 
physicochemical properties, and a large number of SNPs collected thanks to a specific 
microarray. This could enable a meaningful comparison of phenotypes in a challenging 
context. 
MATERIALS AND METHODS 
Overview 
In this work, we use a model previously developed to fit the data from a real example for a 
molecule in early clinical development at IRIS (Motivating data example section). For this 
work we have simulated PK profiles using the model and parameters based on the real data 
to derive phenotypes (PK phenotypes section), on which we have applied different 
association methods (Statistical methods for genetic association section). We have simulated 
scenarios (Simulation study section) for different experimental protocols varying especially 
the number of subjects and evaluate the methods in term of detection probability 
(Evaluation section). 
Motivating data example 
The simulation study was inspired by a real dataset which we cannot use for confidentiality 
issues, but which presented characteristic features encountered during the early phases of 
drug development, including frequent PK sampling, extensive genetic data, a complex PK 
profile and a wide range of doses. We start by describing the clinical study and the 
experimental protocols, as well as the model that will be used in the simulation study. 
Drug S developed by IRIS was investigated in three phase I clinical studies performed in a 
total of 78 adult healthy volunteers. All subjects were genotyped at baseline using a DNA 
microarray developed by the laboratory. This chip has been developed specifically for PK 
studies and consists only of SNPs known for being involved in the PK of drugs, i.e. markers of 
phase I and II metabolic enzymes, of SLC or ABC family transports, as well as nuclear 
receptor genes. The studies included 8 dose groups (5, 10, 20, 50, 100, 200, 400 or 800 units) 
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with different allocations (respectively 6, 6, 24, 12, 12, 6, 6 and 6 subjects by dose) and 
extensive PK sampling. 
A two-compartment model with a double absorption function (Fig. 1, Table I) was used to 
describe the PK of drug S. The nonlinearity with dose was due to the low solubility of drug S, 
and was modelled through a dependency of the absorption parameters F and FRAC on dose. 
The relationship of F with dose was expressed through an Imax model (5) parameterised in 
ImaxF and D50F while the relationship of FRAC with dose was expressed with an Emax model 
(5) parametrised in EmaxFRAC and D50FRAC. Tk0 is the zero order absorption constant rate and 
Tlag1 the corresponding lag time, Ka the first order absorption constant rate and Tlag2 the 
corresponding lag time, V1 the central compartment volume, V2 the peripheral 
compartment volume, Q the intercompartmental clearance and CL the elimination 
clearance. Interindividual variability was described by an exponential model on F, Tk0, Tlag2, 
V2, Q and CL. 
Pharmacokinetic phenotypes 
To capture the PK signal, we considered 3 types of measures in this study. 
Observed concentrations  
Observed concentrations are easy to obtain and require no additional analysis step. Here we 
considered the last concentration at 192h after a single dose administration (C192h), and 
the concentration at 24h (C24h), which corresponds to a trough concentration when 
repeated doses are given during routine treatment. 
Noncompartmental approach 
AUC was calculated using the linear trapezoidal rule and extrapolation to infinity was 
achieved assuming an exponential decay (5,18). 
Normalisation of observed and NCA phenotypes 
To take into account the nonlinearity in dose absorption, observed concentrations C24h and 
C192h, and AUC obtained by NCA were normalised by dose. An Emax model (5) of 
phenotype on dose was fitted for each dataset: 
𝑃ℎ𝑒𝑛𝑜𝑡𝑦𝑝𝑒𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑𝑑 =
𝐸𝑚𝑎𝑥 × 𝑑𝑜𝑠𝑒
𝐸𝐷50 + 𝑑𝑜𝑠𝑒
 
where 𝐸𝑚𝑎𝑥 is the maximal value for predicted phenotype, 𝐸𝐷50 the dose to obtain 50% of 
this maximum and dose the administrated amount. Phenotypes predicted by the model at 
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dose d (𝑃ℎ𝑒𝑛𝑜𝑡𝑦𝑝𝑒𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑𝑑) and reference dose of 20 units (𝑃ℎ𝑒𝑛𝑜𝑡𝑦𝑝𝑒𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑20) were 
used to normalise the phenotype observed at dose d (𝑃ℎ𝑒𝑛𝑜𝑡𝑦𝑝𝑒𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑𝑑) as follow: 
𝑃ℎ𝑒𝑛𝑜𝑡𝑦𝑝𝑒𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑𝑑 =
𝑃ℎ𝑒𝑛𝑜𝑡𝑦𝑝𝑒𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑20
𝑃ℎ𝑒𝑛𝑜𝑡𝑦𝑝𝑒𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑𝑑
× 𝑃ℎ𝑒𝑛𝑜𝑡𝑦𝑝𝑒𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑𝑑 
Model-based approach 
Considering N subjects, sampled at one or ni times, the concentration 𝑦𝑖𝑗 measured in a 
subject 𝑖 receiving a dose 𝐷𝑖  at time 𝑡𝑖𝑗, is described by a nonlinear function (19) 𝑓 such as: 
𝑦𝑖𝑗 = 𝑓(𝜃𝑖; 𝐷𝑖 , 𝑡𝑖𝑗) + 𝜀𝑖𝑗 
where 𝜃𝑖  is the vector of individual parameters assumed to follow a log-normal distribution: 
𝜃𝑖 = 𝜇𝑒
𝜂𝑖  
with 𝜇 the population average parameter and 𝜂𝑖  the difference between the population 
average and the individual 𝑖 parameter. We assumed that PK parameters follow a log-normal 
distribution to ensure that they are strictly positives (20). 
𝜀𝑖𝑗 is the residual effect that quantifies the deviation between the model prediction and the 
measured value for subject 𝑖 at time𝑗. The residual variability was described using a 
proportional model: 
𝑔(𝜃𝑖; 𝑡𝑖𝑗) = 𝜎𝑠𝑙𝑜𝑝𝑒 (𝑓(𝜃𝑖; 𝑡𝑖𝑗)) 
where 𝜎𝑠𝑙𝑜𝑝𝑒 represents the proportional component. We typically assume 𝜂𝑖~𝑁(0, 𝜔
2) and 
𝜀𝑖𝑗~𝑁(0, 𝜎
2). 
Statistical methods for genetic association 
We assume that a linear model links the phenotype to the genetic variants as in: 
𝑃ℎ𝑒𝑛𝑜𝑡𝑦𝑝𝑒𝑖 = 𝛽0 + ∑ 𝛽𝑘. 𝑆𝑁𝑃𝑖𝑘 + 𝜀𝑖 ;  𝑆𝑁𝑃𝑖𝑘 = {0, 1, 2} 
where 𝑃ℎ𝑒𝑛𝑜𝑡𝑦𝑝𝑒𝑖  is a vector for individual phenotypes, 𝛽0 an intercept, 𝑆𝑁𝑃𝑖𝑘 a vector for 
the genetic variants and 𝛽𝑘 a vector for the individual genetic effect size associated to the 
genetic variant and 𝜀𝑖 a residual error following a Gaussian distribution. In this model, the 
genetic variant takes values 0, 1 or 2, reflecting the number of mutated alleles. All 
phenotypes are log-transformed to ensure that they follow a normal distribution. To account 
for type I error inflation due to the multiplicity of tests, all methods used a Sidak correction 
on the Family Wise Error Rate (FWER) to compute a type I error per SNP α: 
𝛼 = 1 − (1 − 𝐹𝑊𝐸𝑅)
1
𝑁𝑡×𝑃𝑡 
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where 𝑁𝑡 and 𝑃𝑡 are the numbers of SNPs and PK parameters considered simultaneously. 
Ridge regression 
Ridge regression imposes a penalty on the size of the 𝛽𝑘 to reduce the prediction error (15) 
without preventing the integration of the model variables. We used the approach proposed 
by Cule et al. to set semi-automatically the penalty so that the trace of the projection matrix, 
which relates the predictions to the observations, is equal to the number of components in a 
principal component analysis (PCA) of the data. From a Bayesian perspective, this 
correspond to applying a Gaussian prior of identical variance on the eigenvalues issued from 
the PCA (21). The ridge regression do not shrunk coefficients estimates to 0. Therefore we 
used a Wald test on these coefficients and their standard error (SE), as proposed by Cule et 
al. (15) to perform the variable selection with the test statistic 𝑇0: 
𝑇0 =
𝛽𝑘
𝑆𝐸(𝛽𝑘)
 
where 𝑆𝐸(𝛽𝑘) is the standard error of the regression coefficient 𝛽𝑘. Under the null 
hypothesis, 𝑇0 follows a Student t distribution with a significant threshold equal to the type I 
error per SNP α. 
Lasso 
Lasso (16) also uses a penalty function, which from a Bayesian point of view corresponds to 
using a double-exponential (DE) probability density as a prior on 𝛽𝑘. The Lasso sets some 
coefficients to 0 for sufficiently large values of the tuning parameter; this allows variable 
selection and ensures a parsimonious model. The regularisation parameter 𝜉 is calculated to 
achieve a target FWER, using the following expression (17): 
𝜉 = 𝛷−1 (1 −
𝛼
2
) √
𝑁
𝜎2
 
where α is the type I error per SNP, 𝛷−1 is the inverse normal distribution function, N the 
number of subjects and σ the standard error of the phenotype considered. 
HyperLasso 
HyperLasso (17) is derived from the Lasso. Here the penalisation corresponds to using a 
normal-exponential gamma (NEG) distribution as a prior on 𝛽𝑘 and depends on two 
parameters: a shape parameter 𝜆 and a scale parameter 𝛾. The sharp peak at zero and the 
flatter tail of the NEG distribution favour sparse solutions but the estimates of larger effects 
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are shrunken less severely than the Lasso. The smaller the shape parameter the heavier the 
tails of the distribution and the more peaked at zero, which can result in fewer correlated 
SNPs being selected. The shape parameter 𝜆 was set to 1 in our study, which gives realistic 
effect size distributions (22). As for Lasso, the scale parameter 𝛾 is calculated, again 
depending on a type I error per SNP α, using the following expression (17): 
𝑠𝑖𝑔𝑛(𝛽)(2𝜆 + 1)
𝛾
𝐷
−(2𝜆+2)(
|𝛽|
𝛾
)
𝐷
−(2𝜆+1)(
|𝛽|
𝛾
)
= 𝛷−1 (1 −
𝛼
2
) √
𝑁
𝜎2
 
where α is the type I error per SNP and D the parabolic cylinder function (23). 
Stepwise procedure  
We use the algorithm in Figure 2 inspired by Lehr et al. (24) and based on univariate 
regression: (i) PK phenotypes are regressed on each SNP and a Wald test is applied with a 
significance threshold equal to α. To account for linkage disequilibrium, among selected 
SNPs showing strong correlation (r² > 0.8), only the most significant is kept. Then (ii) the 
most significant among selected SNPs is included in the linear regression of the PK 
phenotype on the SNPs. These iterative steps are performed until no more SNP enter the 
linear model. 
Simulation study 
Genotypes 
SNPs were simulated using the Hapgen2 software (25) based on the DNA microarray used in 
clinical studies. To simulate genetic variants for the 200 data sets while retaining the 
correlations between variants found in the human genome, we used a reference panel of 
Hapmap genotypes data set (Hapmap 3 release 2) for a Caucasian population (26). Hapgen2 
simulates genotype with the same LD patterns as the reference data (25).  
Summaries of simulated genotypes, i.e. minor allele frequencies, Hardy-Weinberg 
equilibrium and LD plots, can be found in supplementary file (Simulated polymorphisms 
information).  
Pharmacokinetic profiles  
Using the model and parameters estimates from the motivating data example (Table I), we 
simulated concentrations after a single dose administration according to an extensive 
sampling schedule with 16 samples per subject at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 
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96, 120 and 192 hours after taking the tablet. We did not include a limit of quantification 
(LOQ) and the data were simulated without censoring. NCA method was applied on these 
simulated profiles and for the model-based approach, population and individual parameters 
were re-estimated using the Monolix software (27) and SAEM estimation algorithm (28). 
Individual CL, Q and V2 were used as PK phenotype in a post-model covariate analysis step. 
In each simulation scenario, we performed two simulations: in the first simulation (null 
hypothesis H0) we assumed there was no effect of genetics on the PK parameters; in the 
second simulation (alternative hypothesis H1), 6 SNPs were drawn randomly and we 
assumed they had an impact on the log-transformed clearance according to the following 
model: 
𝑙𝑜𝑔(𝐶𝐿𝑖) = 𝑙𝑜𝑔(𝜇𝐶𝐿) + ∑ 𝛽𝑘 × 𝑆𝑁𝑃𝑖𝑘
6
𝑘=1
+ 𝜂𝑖𝐶𝐿  
where 𝐶𝐿𝑖 is the individual clearance, 𝜇𝐶𝐿 the population clearance, 𝛽𝑘 the effect size 
associated to the genotype 𝑆𝑁𝑃𝑖𝑘 and 𝜂𝑖𝐶𝐿  the interindividual variability in clearance.  
For each SNP, the associated effect size 𝛽𝑘 is computed as a function of the coefficient of 
genetic component (𝑅𝐺𝐶𝑘) and the minor allele fraction (𝑝𝑘), according to the following 
equation: 
𝛽𝑘 = √
𝑅𝐺𝐶 𝑘 × 𝜔
2
𝐶𝐿
2𝑝𝑘(1 − 𝑝𝑘) − 𝑅𝐺𝐶 𝑘 × 2𝑝𝑘(1 − 𝑝𝑘)
 
where 𝑅𝐺𝐶 𝑘is the part of the interindividual variability in CL explained by the SNP (expressed 
in %) and 𝜔2𝐶𝐿 is the variance of random effects on CL due to non-genetic sources.  
To simulate realistic genetic effects, the 6 SNPs altogether explained a total 𝑅𝐺𝐶 of 30% with 
unbalanced effect sizes (𝑅𝐺𝐶 𝑘respectively equal to 1, 2, 3, 5, 7 and 12%). These effect sizes 
were chosen to be consistent with genetic effects observed in clinical studies. For example 
warfarin doses has been associated with three genetic variants in the cytochrome P450 
warfarin-metabolizing genes CYP4F2 and CYP2C9 and in the warfarin drug target VKORC1, 
explaining respectively 1.5, 12 and 30% of variability (29). 
Simulation scenarios 
We simulated different scenarios. In the first scenario Sreal, the design was chosen to be close 
to the drug S Phase I clinical trials protocol: 78 subjects (N) receiving 8 different doses (5, 10, 
10 
 
20, 50, 100, 200, 400 or 800 units) with a similar allocation ratio and 16 sampled times (n) at 
0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, 120 and 192h. A second scenario Slarge using the 
same design but with more subjects (N = 384, n = 16) was considered as well to investigate a 
large sample situation. This scenario represents an ideal case from a design perspective, with 
a large number of subjects and a rich protocol for each subject. Figure 3 represents the PK 
profiles from a simulated data set with Slarge design as function of the genotypes of the SNP 
explaining 12% of the clearance interindividual variability (under the alternative hypothesis 
H1). The profiles show an important interindividual variability. As expected last 
concentrations are lower in heterozygotes and rare homozygotes under H1, due to the 
increase of clearances. 
To evaluate the effect of the PK model structure including the nonlinearity of absorption, 3 
additional scenarios were simulated using the same design than Slarge but different structural 
models: a nonlinear absorption without interindividual variability on F (Slarge, no IIV_F), a linear 
PK (SlinearPK: FRAC=0.5, F=0.8, (F)=32.9%) and a linear PK without variability on F  
(SlinearPK, no IIV_F: FRAC=0.5, F=0.8, (F)=0). 
Evaluation 
Each method: ridge regression, Lasso, HyperLasso and the stepwise procedure was applied 
to each PK phenotype: observed C24h and C192h, AUC estimated by NCA and model 
parameters CL, V and Q estimated by NLMEM. To enable proper power comparison the 
target FWER was set to 20% (with a prediction interval for 200 data sets equal to [14.5-
25.5]). Under H0, an empirical FWER was estimated as the percentage of data sets where at 
least one SNP was found significant. If necessary, the type I error per SNP α were corrected 
empirically until the FWER estimate was not significantly different from 20%. Under H1, we 
recorded for each method and phenotype the number of true positives (TP, corresponding 
to the selection of a SNP which was indeed associated to CL in the simulation, its maximum 
over the 200 simulations being 1200) and false positives (FP, corresponding to a SNP 
selected in the model but not present in the simulation). A 95% confidence interval was also 
estimated assuming the number of TP or FP follows a Poisson distribution. The true positive 
rate (TPR) and the false positive rate (FPR) were calculated as follow:  
𝑇𝑃𝑅 =
𝑇𝑃
𝑇𝑃 + 𝐹𝑁
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𝐹𝑃𝑅 =
𝐹𝑃
𝐹𝑃 + 𝑇𝑁
 
where FN is the count of false negatives and TN the count of true negatives. The TPR was the 
main outcome on which we statistically compared the different methods and phenotypes. 
First, we compared the TPR across the different phenotypes for each method, using 
Cochran’s Q test (30) in the following way: for each dataset and each phenotype, we defined 
a variable X with value 1 for the phenotype(s) with the maximal TPR, and 0 for the other 
ones; this was done separately for each method. A global test for each method was 
performed first, with a significance threshold set to 5%; if the phenotypes were found to be 
significantly different, pairwise comparisons were then performed with a Wilcoxon test, 
using a Sidak correction for the number of tests (a corrected threshold of 0.009 for 6 
pairwise comparisons). 
Once the phenotype yielding the highest TPR across the different methods has been 
selected, the same approach was applied to compare methods on this phenotype. In each 
simulation, we also recorded the number of datasets for which all methods detected the 
same number of SNPs (X=1 for all methods), and the number of datasets for which all 
methods failed to detect at least one SNP (X=0 for all methods). 
The probability to detect a given number x (x=1, …, 6) of the 6 SNPs which were associated 
to CL was computed as the percentage of data sets simulated under H1 where x or more 
SNPs are selected. Of note, for the model-based analysis, associations were explored on 
parameters CL, Q and V2. TP were causal variants associated to CL and FP were non-causal 
variants associated to CL and any variants associated to Q and V2. The FPR for the model-
based phenotype designed by CL were then computed by taking into account the FP on 
any of the three model parameters. 
RESULTS 
Scenario 1: Sreal 
Control of FWER under H0 
Table II shows the estimates of the empirical FWER under H0. All methods tended to be too 
conservative since the FWER was lower than expected for all methods and phenotypes, 
except on the last concentration parameter C192h. After an empirical correction of 
thresholds or penalisation parameters depending on the method, FWER was properly 
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controlled around 20%, as shown in Table II. This correction was applied in the 
corresponding simulation under H1. 
To investigate why the FWER was not controlled under H0 despite the calibration step within 
each method, we simulated a scenario Sindependent similar in design to Sreal but with 
independent SNPs. The FWER estimates in Sindependent were non-significantly different from 
20% (results in supplementary materials). This suggests that correlations between SNPs lead 
to a decrease in FWER. 
Performance under H1 
In each scenario, the total number of SNP associated with the PK was 1200, but only a small 
number was effectively detected, as shown in Table III. This was even more apparent for 
associations based on NCA parameter or observed concentrations. The TPR was significantly 
different between the different phenotypes (p<0.001 for each of the 4 methods, according 
to Cochran’s Q test) and was highest for CL in each 2 by 2 phenotype tests (p<0.002 for all 
pairwise comparisons). The FPR on the other hand was similar for all phenotypes (figure 4a). 
The methods were then compared for CL, and the TPR was found to be significantly different 
between the four methods (p<0.001). Ridge regression yielded a higher TPR more often than 
other methods (p<0.003 for all pairwise comparison), while Lasso, HyperLasso and the 
stepwise procedure were comparable.  
The probability to detect at least one genetic variant on CL estimates was low, around 40% 
for all methods (Fig. 5a). This probability decreased quickly when trying to detect more 
variants and reached 0 for 3 variants or more.  
Scenario 2: Slarge 
Control of FWER under H0 
As expected due to the larger number of subjects, the estimated FWER increased with 
comparison to the scenario Sreal, but remained below the target of 20% for some methods. 
Empirically corrected thresholds and penalty terms were determined for each combination 
of phenotype and method to obtain FWER estimates of 20% and were then used for the 
simulations under H1 (results in supplementary materials).  
Performance under H1 
The number of TP increased clearly compared to the previous scenario (Table IV). 
Concerning the comparison between phenotypes we found similar results as for Sreal: all 
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methods were more powerful when applied to CL compared to the other phenotypes 
(p<0.001 for all pairwise comparison). The number of FP also increased and was quite high, 
but increased proportionally less than the number of TP for the model-based phenotypes, 
C192h and AUC. For C24h on the other hand, the number of FP exceeded the number of TP. 
Thus for a similar FPR between all phenotypes, the TPR was higher for CL (Fig. 4b). The TPR 
for ridge regression was higher than Lasso and HyperLasso (p<0.001 with methods applied to 
CL). The TPR for the stepwise procedure was intermediate, the 2 by 2 tests were not 
significant for the comparison of the stepwise procedure versus ridge regression or Lasso. 
As expected, with increasing the number of subjects the power of all methods increased to 
reach almost 100% to detect at least one genetic variant (Fig. 5b). Then, the power 
decreased when trying to detect more variants. Departure in methods was observed on the 
power to detect at least 3 and more variants, with the ridge regression and stepwise 
procedure showing higher power.  
Influence of the structural PK model under H1  
In both scenarios, regardless of the association method, the power to detect a gene effect 
was higher using PK parameter obtained by NLMEM than AUC estimated by NCA or 
observations. We investigated whether this was due to the specific features in the PK model, 
i.e. the non-linearity in the absorption model and/or the variability in the bioavailability. 
When we assumed no variability on the bioavailability parameter F (scenario Slarge, noIIV_F), the 
difference in the number of TP between CL and AUC was smaller (Fig. 4c), but the TPR for CL 
remained higher compared to AUC. Assuming a linear absorption, while retaining variability 
on F, also reduced this difference (scenario SlinearPK, Fig. 4d) but only when we used a linear 
absorption model without variability on F did the benefit of CL over AUC disappear (scenario 
SlinearPK, noIIV_F, results in supplementary materials). Changes in the PK structural model did not 
affect the number of TP for C192h, while removing the variability on bioavailability increased 
the number of TP for C24h, although it remained very low. 
DISCUSSION 
Many analysis methods have been proposed in the pharmacogenetic literature, depending 
on the phenotypes studied and the association test. NCA is mainly used to represent the PK 
exposure, univariate association methods are still widely applied and sample sizes are 
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limited. This work aimed to evaluate 16 combinations of four phenotypes and four methods 
and the design of the different simulation scenarios was based on actual clinical studies. This 
realistic setting enabled a meaningful comparison, providing at the same time a challenging 
context of nonlinear PK and a custom set of polymorphisms. 
This work takes place in context of exploratory analyses, and we therefore chose a high 
FWER for variable selection (20%). The four association methods use estimated phenotypes 
after an initial estimation step without covariates included in the model. Work on alternative 
approaches which simultaneously estimate the PK model parameters and the genetic size 
effects are ongoing (31); they require iterative selection and estimation which increases the 
computational burden. We decided to study the most common association methods based 
on a maximum likelihood approach, the ridge regression and Lasso, together with a specific 
extension for genetic covariates (HyperLasso). Other penalized regression methods have 
been proposed such as the elastic net method (32), which has shown intermediate 
performances between ridge regression and Lasso. Other approaches to investigate include 
modifications of the penalised methods we used, such as the significance test very recently 
developed for the Lasso (33). In the present work, we did not consider gene-gene and gene-
environment interactions. Model-based approaches have been proposed in such contexts, 
and evaluated on real pharmacogenetic data sets (34). These methods or clustering based 
algorithms should be compared to penalized regression methods in simulations close to 
those presented in this work. Frequentist approaches are most often used in population 
PK/PD analysis. Bayesian methods (35) may also be worth considering for variable selection 
but there use remains limited in population PK/PD studies. The estimate of entire 
distributions of parameters adds an additional numerical complexity requiring further 
development beyond the scope of the present work. 
Several methodological works associating pharmacogenetics and NLMEM have been 
published (36–39). Lehr et al. have suggested an adaptation of the classical stepwise 
covariate selection on PK phenotype in NLMEM (24) and a method inspired from Lasso has 
already been used for the selection of non-genetic covariates in NLMEM (40). But this is the 
first work comparing model-based approach with NCA in this area. In our study, all methods 
showed a higher number of TP when used on individual clearances CL from NLMEM, 
compared to the other phenotypes (AUC, C24h, and C192h). Furthermore, relatively to the 
number of TP, the number of FP was lower for model-based phenotypes (CL, Q and V2) than 
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other phenotypes, also improving the TPR. This finding indicates that using a modelling 
approach enables better power. Indeed, the modelling approach allows separating the 
different phases of the PK process (absorption, distribution, metabolism, excretion), 
improving the interpretation of the genetic effects by the comprehension of mechanisms 
behind the association between a genetic and a primary PK parameter. The benefits 
provided by this approach compared to the NCA in terms of power have also been shown in 
other areas (41,42), especially when the number of samples per subject is limited, but 
remained to be demonstrated in the field of pharmacogenetics. In the simulation we did not 
include a LOQ and the data were simulated without censoring.  In practice however late 
measurement of last concentrations could entail a significant number of data below LOQ 
which would decrease the ability to detect genetic differences. We would expect the NCA 
approach to be also impacted, as data below the LOQ are usually omitted in NCA, resulting 
in bias in parameters estimated through such approach (43). In NLMEM on the other hand 
different methods based on likelihood have been developed to impute values below the LOQ 
in NLMEM (44), resulting in unbiased estimates. With such methods, presence of data below 
the LOQ should not modify the probability to detect genetic effects on phenotypes 
estimated through NLMEM.   
AUC is highly correlated with CL (𝐴𝑈𝐶 =
𝐷𝑜𝑠𝑒
𝐶𝐿
) when the number of samples per subject is 
large, as in design used in simulations. Despite this the power to detect a gene effect was 
higher for the model-based approach than for the phenotypes estimated by NCA or 
observed due to the specific features in the PK model, the nonlinearity in the absorption 
model and the variability in the bioavailability. Indeed, with a linear absorption and no 
variability on the bioavailability parameter F (scenario SlinearPK, noIIV_F), the TPR is similar 
between CL and AUC (results in supplementary materials). Still in the linear case, an 
interindividual variability on F reduces the TPR of AUC (scenario SlinearPK). In the nonlinear 
case, although the phenotypes observed or estimated by NCA are normalised, because of 
estimation errors in the Emax model used for the normalisation, their respective TPR are 
lower than CL, even with no variability on F (scenario Slarge, noIIV_F). In such a rich design, 
where the subjects are extensively sampled, AUC is appropriate when the PK is simple 
(linear, without variability on the absorption process). 
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In our simulations we introduced effects from six SNPs on CL parameter in the PK model to 
simulate concentrations profiles under the alternative hypothesis. These settings may favour 
the model-based phenotypes and also by extension AUC which is directly correlated with CL. 
With a nonlinear PK model model-based phenotypes proved much more powerful compared 
to the phenotype estimated by NCA, even correcting the AUC by dose to take into account 
the nonlinearity. On the other hand, when the PK model was linear, we found similar results 
in terms of TPR and FPR for both phenotypes, but only when there was no interindividual 
variability on bioavailability. Concerning the observed phenotypes we expected the late 
concentration C192h to be a good reflection of clearance, and to give similar performance 
than CL after correction for nonlinearity. However, this was not the case in our results, even 
with a linear PK. The reason for this is probably that the influence of the other parameters 
dilutes the impact of the genotypes on this observed phenotype, while AUC only depends on 
CL. But the results in term of TP obtain on C192h were better than on C24h. This 
concentration is not informative for elimination clearance because occurring for many 
subjects during the rebound simulated using our PK model, so that the poor performance for 
this phenotype could be expected. 
In the model-based approach, using NLMEM individual parameter estimates are derived 
after the estimation of the population parameters and their precision depends on the 
amount of individual information available in the data (45). In the scenarios we simulated, 
the number of sampling points per subject was large, so that all model parameters, included 
the phenotype, were well estimated. The number of TP obtained using the simulated 
clearances (without the estimation step) in both scenarios was only slightly higher than 
when using the estimated clearance. 
The estimates of the probability to detect causal variants were similar between methods in 
scenario Sreal, while a departure was noticed in scenario Slarge to detect at least 3 variants. 
The ridge regression method exhibited the highest count of TP but to the cost of a higher 
number of FP. In scenario Sreal the estimates were rather low and fell to nearly 0% for the 
probability to detect at least 3 of the 6 SNPs, indicating a low ability to detect multiple 
effects in a realistic design. As expected, increasing the number of subjects (scenario Slarge) 
strongly increased the probability of the different methods to detect more variants. But 
detecting all the 6 simulated variants remained very rare, due to the small percentage of 
variability explained by some variants. Our simulations illustrate the importance of the 
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number of subjects in pharmacogenetic studies : infrequent mutations are unobserved in a 
small population and association methods are sensitive to the frequency of the variant allele 
(39). 
All methods were fast to run, requiring several minutes to several hours depending on the 
number of subjects in the scenario. Despite its iterative algorithm, stepwise procedure using 
univariate regression was the simplest and fastest method in all scenarios. However, the use 
of a full stepwise procedure using model estimation like proposed by Lehr et al. (24) causes a 
sharp increase in run time (39). Ridge regression and Lasso were intermediate methods in 
term of run time and HyperLasso was the slowest method. 
There have been few papers comparing association methods in pharmacogenetics applied to 
PK/PD. The present work complements a previous study by Bertrand and Balding (39), who 
compared four association methods (ridge regression, Lasso, HyperLasso and a stepwise 
procedure) on only one kind of PK phenotype, CL estimated by NLMEM. Their setup is close 
to our scenario Slarge in terms of the number of subjects (N=300), but each subject was 
sampled only 6 times. We compared the number of TP and FP between our studies. Our 
results for model-based phenotypes are partly different from those presented in this study. 
Bertrand and Balding found both fewer TP and less FP than in the Slarge scenario. These 
differences result from our respective calculations of TP and FP. In Bertrand and Balding (39) 
causal variants were removed from the analysis data sets and TP were defined as SNPs 
correlated with the causal variants with an r²>0.05. In our study on the other hand, the 
causal variants were present in the analysis data sets. Using the calculations of Bertrand and 
Balding, we obtained similar numbers of FP but the numbers of TP remained higher. 
Bertrand and Balding also explored 1227 SNPs, i.e. 7 times more SNPs in a similar number of 
subjects. In the ridge regression, the threshold for the Wald test proposed by Cule et al. (15) 
was therefore much more stringent which could explain that ridge regression detected 
fewer TP than the other shrinkage based approaches in their study. 
In conclusion this work shows the critical importance of using modeling approaches for 
pharmacogenetic studies. They allow detecting associations between genetic variants and PK 
more efficiently, in particular in the presence of complex PK involving non-linearity, where 
the AUC even corrected for the dose effect was much less sensitive to the genetic effect. In 
addition the use of models allows for the analysis of intrinsic parameters with physiological 
meaning as an elimination or an absorption rate. Our results also reinforce the importance 
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of the number of subjects in pharmacogenetic studies, and suggest that it may not be 
reasonable to expect to detect even strong genetic effects and/or genetic effect due to rare 
alleles with small sample sizes. In addition, this work has highlighted statistical difficulties; 
FWER was not properly controlled and lower than expected. An empirical correction had to 
be performed to target 20% for the FWER. This decrease was due to the correlation between 
SNPs, as we showed in an additional simulation with uncorrelated genotypes. Consequently, 
to enable the comparison across the different methods, the FWER was set empirically for the 
16 combinations of methods and phenotypes. A final message from this work is that in our 
simulation settings no association method showed a much higher power than the others.  
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Table I. Population values (µ) and interindividual variability (ω) for drug S model (units not disclosed 
for confidentiality reasons) 
Parameters µ ω (%) 
Fa 
ImaxF 0.8 
32.9 
D50F 41.7 
FRACb 
EmaxFRAC 0.45 
- 
D50FRAC 18.6 
Tlag1  
0.401 35.1 
Tk0 
 
1.59 31.6 
Tlag2  
22.7 - 
Ka 
 
0.203 - 
V1 
 
1520 - 
Q 
 
147 89.9 
V2 
 
2130 44.2 
CL 
 
94.9 25.1 
σslope (%)   20 - 
a. For doses strictly inferior to 20 units 𝑭 = 𝟏, for doses superior or equal to 20 units   
𝑭 = 𝟏 −
 𝑰𝒎𝒂𝒙𝑭 (𝒅𝒐𝒔𝒆 − 𝟐𝟎)
𝑫𝟓𝟎𝑭 + 𝒅𝒐𝒔𝒆 − 𝟐𝟎 
, where dose is the administrated amount. 
b. 𝐹𝑅𝐴𝐶 =
𝐸𝑚𝑎𝑥𝐹𝑅𝐴𝐶 𝑑𝑜𝑠𝑒 
𝐷50𝐹𝑅𝐴𝐶 + 𝑑𝑜𝑠𝑒 
, where dose is the administrated amount. 
 
 
 
Table II. Empirical estimates of Family-Wise Error Rate under H0 for Sreal scenario 
     FWER 
Method   C24h C192h AUC CL 
Ridge regression without correctiona 13 21 15.5 9.5 
Lasso without correctiona 12 20.5 11.5 12 
HyperLasso without correctiona 10.5 17.5 11 11 
Stepwise procedure without correctiona 14.5 23.5 14.5 14.5 
Ridge regression after empirical correctionb 19 21 20.5 19.5 
Lasso after empirical correctionb 18 20.5 18.5 19.5 
HyperLasso after empirical correctionb 18 17.5 18 19 
Stepwise procedure after empirical correctionb 18.5 23.5 19 18 
a. Set of empirical family wise error rates (FWER) obtain without correction. 
b. Set of empirical FWER obtain after correction of thresholds or penalisation parameters. 
The 95% prediction interval around 20 for 200 simulated data sets is [14.5-25.5]. 
 
 
Table III. Counts of true and false positives under the alternative hypothesis for Sreal scenario 
Method   C24h C192h AUC CL Q V2 
Ridge regression TP 25 [16;37] 70 [55;88] 49 [36;65] 107 [88;129] - - 
Lasso TP 20 [12;31] 50 [37;66] 43 [31;58] 86 [69;106] - - 
HyperLasso TP 14 [8;23] 42 [30;57] 33 [23;46] 79 [63;98] - - 
Stepwise procedure TP 17 [10;27] 52 [39;68] 33 [23;46] 80 [63;100] - - 
Ridge regression FP 79 [63;98] 125 [104;149] 97 [79;118] 97 [79;118] 42 [30;57] 29 [19;42] 
Lasso FP 70 [55;88] 73 [57;92] 76 [60;95] 54 [41;70] 34 [24;48] 22 [14;33] 
HyperLasso FP 57 [43;74] 55 [41;72] 54 [41;70] 32 [22;45] 32 [22;45] 19 [11;30] 
Stepwise procedure FP 65 [50;83] 72 [56;91] 66 [51;84] 36 [25;50] 36 [25;50] 19 [11;30] 
Total number of true positives (TP) and false positives (FP) with their 95% confidence interval under the alternative hypothesis.  
On 200 simulated data sets, overall 1200 SNPs were set to impact clearance (maximum TP number).  
 
 
Table IV. Counts of true and false positives under the alternative hypothesis for Slarge scenario 
Method   C24h C192h AUC CL Q V2 
Ridge regression TP 96 [78;117] 427 [387;469] 313 [279;350] 624 [576;675] - - 
Lasso TP 89 [71;110] 403 [365;444] 301 [268;337] 563 [517;611] - - 
HyperLasso TP 80 [63;100] 373 [336;413] 277 [245;312] 545 [500;593] - - 
Stepwise procedure TP 91 [73;112] 388 [350;429] 292 [259;327] 590 [543;640] - - 
Ridge regression FP 114 [94;137] 253 [223;286] 206 [179;236] 320 [286;357] 32 [22;45] 51 [38;67] 
Lasso FP 97 [79;118] 163 [139;190] 148 [125;174] 159 [135;186] 40 [29;54] 46 [34;61] 
HyperLasso FP 84 [67;104] 97 [79;118] 99 [80;121] 86 [69;106] 36 [25;50] 42 [30;57] 
Stepwise procedure FP 90 [72;111] 115 [95;138] 127 [106;151] 111 [91;134] 39 [28;53] 43 [31;58] 
Total number of true positives (TP) and false positives (FP) with their 95% confidence interval under the alternative hypothesis.  
On 200 simulated data sets, overall 1200 SNPs were set to impact clearance (maximum TP number). 
 
 
  
 
Fig. 1. Structural PK model of drug S. Double absorption compartments in red and disposition 
compartments in blue 
 
 
 
 
 
Fig. 2. Stepwise procedure algorithm, adapted from Lehr et al. (24) 
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Fig. 3. Individual concentration versus time profiles (blue lines) and mean profiles (red lines) for one 
simulated dataset under H0 (top) and under H1 (bottom), in scenario Slarge. The profiles are plotted in 
log-scale for the Y-axis. The three panels show the profiles for common homozygotes (left), 
heterozygotes (middle) and rare homozygotes (right) 
 
 
 
Fig. 4. Percentage of True Positive Rate (TPR) versus False Positive Rate (FPR) (dots). Each PK 
phenotype is represented by one color and each association method by one symbol. The Sreal 
scenario on top-left with a focus on lower values of TPR and FPR (a), the Slarge scenario on top-right 
(b), the Slarge,noIIVF scenario on bottom-left (c) and the SlinearPK scenario on bottom-right (d) 
 
 
 
Fig. 5. Probability Estimates (dots) and 95% confidence interval (bars) under H1 with each method to 
detect at least x variants explaining interindividual variability of CL, with x varying from 1 to 6. The 
Sreal scenario on left (a) and the Slarge scenario on right (b) 
 
